Wednesday, July 15, 2009

OVP Ventures Into Limerick BioPharma

Seattle venture capital firm OVP Venture Partners is the lead in the funding of a San Francisco firm developing biopharmaceuticals, according to the firm, Limerick BioPharma. Limerick, which develops compounds for reducing side effects in drug treatments, said that it raised $15M in a Series C funding round from OVP, ARCH Venture Partners, Sevin Rosen Funds and Altitude Funds. OVP's Chad Waite joins Limerick's board along with the funding. Waite also sits on the boards of Accelerator, Adapx, Complete Genomics, GenoLogics, NanoString, Napera Networks, Plectix BioSystems, SafeHarbor, and Verdezyne. More information »